Association between the ERCC1 Polymorphisms and Glioma Risk: A Meta-Analysis of Case-Control Studies

Abstract

Objective: Polymorphisms in DNA repair genes have been shown to influence DNA repair processes and to modify cancer susceptibility. Published data regarding the association between excision repair cross-complementing rodent repair deficiency complementation group1 (ERCC1) polymorphisms and glioma risk have been inconsistent and inconclusive. To acquire a more precise effect of the association between these polymorphisms and glioma risk, a meta-analysis was performed. Methods: Data was collected in PubMed and EMBASE, with the last search up to 30 th August 2013. A total of 6 studies were identified with 2642 cases and 3669 controls for ERCC1 C8092A polymorphism, and 4 studies were identified with 1390 cases and 1546 controls for ERCC1 C118T polymorphism. All of the statistical analyses were performed using statistical data 10.0. Results: The combined results showed that ERCC1 C8092A polymorphism was associated with glioma risk (additive model: OR = 1.10, 95% CI 1.02 - 1.20; recessive model: OR = 1.51, 95% CI 1.24 - 1.85; co-dominant model AA vs. CC: OR = 1.52, 95% CI 1.24 - 1.86). As for ethnicity subgroup analysis, ERCC1 C8092A polymorphism was associated with increased glioma risk among Chinese(additive model: OR = 1.15, 95% CI 1.01 - 1.30; recessive model: OR = 1.34, 95% CI 1.02 - 1.75; AA vs. CC: OR = 1.37, 95% CI 1.03 - 1.81), and so among Caucasian except additive model(recessive model: OR = 1.75, 95% CI 1.31 - 2.34; co-dominant model AA vs. CC: OR = 1.70, 95% CI 1.27 - 2.29). No evidence of an association of ERCC1 C118T polymorphism with glioma was found. Conclusion: The meta-analysis suggested that ERCC1 C8092A polymorphism might be associated with the increased risk of glioma, whereas ERCC1 C118T polymorphism might have no influence on the susceptibility of glioma.